BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epanova: Phase I/II data

The open-label, 4-way crossover, U.S. Phase I/II ECLIPSE trial in 54 healthy volunteers showed that 4 g Epanova produced plasma levels of EPA and DHA that were >4 times higher than the levels achieved with 4 g ...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >